Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.4
Commitments and Contingencies (Details Narrative)
€ in Millions
 1 Months Ended 3 Months Ended
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2022
EUR (€)
Jan. 31, 2019
USD ($)
Loss Contingencies [Line Items]            
Research and development expenses     $ 3,745,940 $ 4,265,866    
Payment to acquire in process research and development     120,000    
Discovery Collaboration Agreements [Member] | XOMA [Member]            
Loss Contingencies [Line Items]            
Milestone payments     $ 3,800,000      
Research and development expenses $ 500,000          
Cellca Agreement [Member]            
Loss Contingencies [Line Items]            
Description of milestone payments     The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.      
Cellca Agreement [Member] | Maximum [Member]            
Loss Contingencies [Line Items]            
Milestone payments           $ 700,000
The Cellca Agreement [Member]            
Loss Contingencies [Line Items]            
Milestone payments     $ 600,000      
The Cellca Agreement [Member] | In Process Research and Development [Member]            
Loss Contingencies [Line Items]            
Commercial product license fee payment Obligation $ 100,000          
The Cellca Agreement [Member] | Maximum [Member]            
Loss Contingencies [Line Items]            
Payment for annual license fee obligation     600,000      
The Cellca Agreement [Member] | Minimum [Member]            
Loss Contingencies [Line Items]            
Payment for annual license fee obligation     100,000      
The Brink Agreement [Member]            
Loss Contingencies [Line Items]            
Commercial product license fee payment Obligation     100,000      
The Brink Agreement [Member] | In Process Research and Development [Member]            
Loss Contingencies [Line Items]            
Commercial product license fee payment Obligation     100,000      
Invivo Gen Agreement [Member]            
Loss Contingencies [Line Items]            
Payment for annual license fee obligation     100,000   € 0.1  
Proteo Nic Agreement [Member]            
Loss Contingencies [Line Items]            
Milestone payments     1,300,000   € 1.2  
Proteo Nic Agreement [Member] | In Process Research and Development [Member]            
Loss Contingencies [Line Items]            
Annual license fee   $ 24,600        
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]            
Loss Contingencies [Line Items]            
Milestone payments     1,000,000.0      
Research and development expenses     $ 100,000      
Payment to acquire in process research and development       $ 100,000